Results 1 to 10 of about 12,566 (192)

An Unexpected Result of Obesity Treatment: Orlistat-Related Acute Pancreatitis

open access: yesCase Reports in Gastroenterology, 2015
Orlistat is a pancreatic lipase inhibitor which is used to treat obesity. Due to the increasing prevalence of obesity, orlistat use is thought to rise progressively. We report an interesting case caused by orlistat use caught in the early stages of acute
Kaan Gök, Tufan Tukek
exaly   +4 more sources

Epithelial SLC25A20 Deficiency Drives Immunosuppressive Neutrophil Remodeling via ARG1 Palmitoylation to Promote Colorectal Cancer. [PDF]

open access: yesAdv Sci (Weinh)
SLC25A20 deficiency in tumor cells compromises mitochondrial LCFA transport, which suppresses FAO and drives compensatory release of palmitic acid‐enriched lipids into the TME. These tumor‐derived palmitic acids are taken up by TANs, promoting ZDHHC18‐catalyzed ARG1 palmitoylation.
Han Y   +8 more
europepmc   +2 more sources

Effect of anti-obesity drug orlistat (Xenical™) on liver and kidney function in male rats fed a high-fat diet [version 2; peer review: 1 approved, 2 approved with reservations] [PDF]

open access: yesF1000Research
Background HFDs have adverse effects on metabolic health, which puts individuals at risk of obesity and liver and kidney dysfunction. Orlistat is an antihypertensive agent against obesity that prevents the absorption of dietary fats, although its impact ...
Asmaa M. Neamah   +4 more
doaj   +2 more sources

The Application of Quantitative 1H-NMR for the Determination of Orlistat in Tablets

open access: yesMolecules, 2017
A quantitative nuclear magnetic resonance (qNMR) method to measure the content of Orlistat in tablets was studied and found to be efficient, accurate, reliable, and simple.
Yinghong Wang, Xiangju Jin, Shanshan Sun
exaly   +3 more sources

The Effect of Orlistat Administration in Change of Glycemic Control and Weight Loss of Obesity or Overweight Patients with Type 2 Diabetes Mellitus

open access: yesFolia Medica Indonesiana, 2022
Hightlight: • The effect of orlistat on glycemic control and weight loss in overweight or obese type 2 diabetes mellitus patients was determined • HbA1c and FPG level in overweight and obese type 2 diabetes mellitus patient can improved by orlistat as
Abu Rizal Dwikatmono Johan   +6 more
doaj   +1 more source

Hepatorenal and cerebellar anti-toxic effects of curcumin against orlistat associated toxicity in obese male albino rats [PDF]

open access: yesEgyptian Journal of Cancer and Biomedical Research, 2022
Background: Orlistat is one of the common medicines in treating overweight, and its use may cause several side effects. Curcumin, a yellow phenolic compound isolated from Curcuma longa's rhizome, possesses several pharmaceutical effects due to its ...
Eman Kandil, Samah Arisha
doaj   +1 more source

Myelopoietic efficacy of orlistat in murine hosts bearing T cell lymphoma: implication in macrophage differentiation and activation. [PDF]

open access: yesPLoS ONE, 2013
Orlistat, an inhibitor of fatty acid synthase (FASN), acts as an antitumor agent by blocking de novo fatty acid synthesis of tumor cells. Although, myelopoiesis also depends on de novo fatty acid synthesis, the effect of orlistat on differentiation of ...
Shiva Kant   +2 more
doaj   +1 more source

Evaluating the Effect of Orlistat Administration on Depressive Behavior in Mice Following Inducing Depression by Water Avoidance Stress Model [PDF]

open access: yesMajallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, 2023
Introduction: The weight-loss drugs can induce depression. Orlistat is one of the common weight-loss drugs, but preclinical studies about its effect on mood have not been performed.
Nazanin Behrooz, Azadeh Mesripour
doaj  

Nephrotoxicity associated with Orlistat in normal and obese female rats [PDF]

open access: yesJournal of Bioscience and Applied Research, 2018
Obesity is a global health concern associated with high morbidity and mortality. Therapeutic strategies include synthetic drugs and surgery, which may entail high costs and serious complications. Orlistat is a pancreatic lipase inhibitor licensed for the
Ehab Tousson   +3 more
doaj   +1 more source

ASSESSING THE EFFECTS OF ORLISTAT AS AN ANTI-OBESITY DRUG IN HIGH FAT DIET INDUCED OBESITY IN MALE RATS [PDF]

open access: yesBulletin of Pharmaceutical Sciences. Assiut University, 2021
The present work was designed to evaluate the effectiveness of the orlistat drug on some hormones and biochemical parameters in male rats received a high fat diet (HFD).
Omnia Abdel-Rahman, Enas Abdel-Baky
doaj   +1 more source

Home - About - Disclaimer - Privacy